At the moment, lacking full data from CARE-MS1 trial and awaiting CARE-MS2 trial results, Lemtrada potential place in the MS arena looks at a distant behind Tysabri, Gilenya, and BG12.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.